1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6FD125595A992E7F8002586960055C1FD
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/FD125595A992E7F8002586960055C1FD?OpenDocument
18
19OpenDocument
2035.170.64.36
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Patient Focused Services Patient Support Programs

Benchmarking Meta-Analysis of New-Product Bridge and Fast-Start Patient Assistance Programs

ID: 5668


Features:

7 Info Graphics

7 Data Graphics

70 Metrics

2 Narratives


Pages/Slides: 17


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Benchmarking Meta-Analysis of New Product Bridge and Fast-Start Patient Assistance Programs"

STUDY OVERVIEW

Patient assistance programs have become important ways for pharma to help patients navigate expensive therapies or new products that are pending coverage by payers.

Fast start programs are typically patient assistance provided for new drugs with pending coverage approval. Bridge programs are patient assistance provided by drug makers to reduce or eliminate costs for eligible individuals.

Best Practices, LLC prepared this research to identify and spotlight current trends and future directions of bridge assistance and fast start programs supporting new biopharmaceutical product programs.

The study probes the prevalence and impact of such bridge programs and examines their role during new product introduction. The research also evaluates bridge programs' role in the context of overall pull through services to help patients get quickly and effectively started on new medicines.

KEY TOPICS

  • Bridge Program Prevalence
  • Bridge Impact Ratings
  • Bridge Programs Have Many Forms
  • Risk of Failed Patient Support Programs
  • Patient Hubs & Hub Services
  • Pandemic Stimulates Increase in Bridge Programs
  • New Field Roles to Support Fast Start & Reimbursement

SAMPLE KEY METRICS
  • Which of the following reflects the impact of each patient support/assistance programs your company is using in response to COVID-19?
  • Estimate the current and future risk level of each patient pitfall that can derail a new product coming into a crowded market
  • How much collaboration do you engage in with your Patient Hub vendor?
  • Does your patient hub offer a full spectrum of services in one package or do you let the patient choose individual services?
  • What do you include in your Patient Support Hub packages / services?

SAMPLE KEY FINDINGS
  • Highly Rated: Bridge Programs are among the most highly-rated patient assistance programs and support services
  • 80% Thumbs Up: 8 of 10 companies using bridge programs rate them as having “high impact.”

METHODOLOGY

Nine benchmarking field studies that included more than 100 companies were used to probe patient assistance programs for this analysis

Industries Profiled:
Pharmaceutical; Health Care; Consumer Products; Biotech; Medical Device; Manufacturing; Diagnostic; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Merck; Merck Serono; Novo Nordisk; Novartis; Lundbeck; CSL Behring; Johnson & Johnson; Biogen; Allergan; Alcon; Bayer; Roche; Sunovion; ViiV Healthcare; Ipsen; Sanofi; AstraZeneca; Takeda Pharmaceuticals; OTSUKA; Genzyme

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.